...
首页> 外文期刊>International Journal of Cell Biology >Endothelial Cells and Astrocytes: AConcerto en Duoin Ischemic Pathophysiology
【24h】

Endothelial Cells and Astrocytes: AConcerto en Duoin Ischemic Pathophysiology

机译:内皮细胞和星形胶质细胞:AConcerto en Duoin缺血性病理生理学

获取原文
           

摘要

The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke.
机译:神经血管/神经胶质血管单位最近在脑缺血研究中得到了越来越多的关注,特别是在星形胶质细胞和内皮细胞中发生的细胞和分子变化方面。在本文中,我们总结了与水肿形成,与基底层的相互作用以及血脑屏障功能障碍有关的这些变化的最新知识。我们还审查了重组组织纤溶酶原激活剂与星形胶质细胞和内皮细胞的关系,重组纤溶酶原激活剂是中风后唯一获得FDA批准的溶栓药物。然而,它具有狭窄的治疗时间窗和严重的临床副作用。最后,我们为将来的缺血性药物开发(例如过氧化物酶体增殖物激活的受体和c-Jun N末端激酶途径的抑制剂)提供了替代治疗靶标。在神经保护药物的开发中,以神经血管单位为保护血脑屏障而不是传统的以神经元为中心的方法,可能会改善中风后的临床结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号